Twist Bioscience (TWST) revenue
Twist Bioscience (TWST) reported revenue of $459.43M in fiscal 2026 (the year ended September 30, 2026). That is 22.0% higher than the $376.57M of fiscal 2025. Figures as of 18 Nov 2026, 10:45 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Revenue, fiscal 2026
- $459.43M
- Change on fiscal 2025
- +22.0%
- Growth, 5 years
- +28.3% a year
- Highest on record
- $459.43Mfiscal 2026
- Lowest on record
- $10.77Mfiscal 2017
- Fiscal years on record
- 102017–2026
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Twist Bioscience revenue, in more detail
Over the five fiscal years to 2026 revenue grew at a compound 28.3% a year. Across the 10 fiscal years on record (2017–2026), the highest was $459.43M in fiscal 2026 and the lowest $10.77M in fiscal 2017.
Revenue by fiscal year
Twist Bioscience revenue, year by year
| Fiscal year | Revenue | Change | Year ended |
|---|---|---|---|
| 2026 | $459.43M | 22.0% up | |
| 2025 | $376.57M | 20.3% up | |
| 2024 | $312.97M | 27.7% up | |
| 2023 | $245.11M | 20.4% up | |
| 2022 | $203.57M | 53.8% up | |
| 2021 | $132.33M | 46.9% up | |
| 2020 | $90.10M | 65.7% up | |
| 2019 | $54.39M | 113.9% up | |
| 2018 | $25.43M | 136.2% up | |
| 2017 | $10.77M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement.
How to read it
Steady growth in revenue is the raw material for everything else; a fall means the company is selling less or charging less.
Revenue at health care companies of similar size
| Company | Revenue | Fiscal year |
|---|---|---|
| TG Therapeutics TGTX | $616.29M | 2025 |
| Praxis Precision Medicines PRAX | $8.55M | 2024 |
| Twist Bioscience TWST | $459.43M | 2026 |
| Protagonist Therapeutics PTGX | $46.02M | 2025 |
| Krystal Biotech KRYS | $389.13M | 2025 |
| 10x Genomics TXG | $642.82M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Twist Bioscience, figure by figure
- Twist Bioscience market cap
- Twist Bioscience earnings
- Twist Bioscience earnings per share (EPS)
- Twist Bioscience P/E ratio
- Twist Bioscience P/S ratio
- Twist Bioscience P/B ratio
- Twist Bioscience free cash flow
- Twist Bioscience operating margin
- Twist Bioscience dividend
- Twist Bioscience shares outstanding
- Twist Bioscience total debt
- Twist Bioscience cash on hand
- Twist Bioscience total assets
- Twist Bioscience return on equity (ROE)
- Twist Bioscience return on invested capital (ROIC)
Twist Bioscience (TWST) overview: price, valuation and scorecardAll health care companies by market value
Twist Bioscience revenue: questions and answers
What is Twist Bioscience's revenue?
Twist Bioscience (TWST) reported revenue of $459.43M in fiscal 2026 (the year ended September 30, 2026). That is 22.0% higher than the $376.57M of fiscal 2025.
What is the growth rate of Twist Bioscience's revenue?
Over the five fiscal years to 2026 revenue grew at a compound 28.3% a year.
What are the highest and lowest revenue figures on record for Twist Bioscience?
Across the 10 fiscal years on record (2017–2026), the highest was $459.43M in fiscal 2026 and the lowest $10.77M in fiscal 2017.
How is Twist Bioscience's revenue calculated?
Revenue is everything the company billed its customers over the fiscal year — the top line of its income statement. For Twist Bioscience it is on record here for 10 fiscal years, 2017 to 2026.
Fiscal years are named for the calendar year they end in.
Learn: revenue
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Twist Bioscience (TWST) revenue”, data as of 18 November 2026. https://funkfolio.com/stock/TWST/revenue
Underlying data: the company's filings with the SEC and Yahoo Finance.